source
- UCB commits $2 billion to Candid's T cell engager program for autoimmune diseasesUCB, a long standing European pharmaceutical company, announced a $2 billion investment in Candid, a biotech focused on T cell engager therapies aimed at autoimmune conditions. The deal reflects U…
- 5th Circuit reinstates in-person dispensing for mifepristone, prompting Supreme Court stay and industry concernsThe 5th Circuit Court of Appeals reversed a prior ruling and required mifepristone to be dispensed only in person. Danco, the drug's maker, asked the Supreme Court for relief and received a one-wee…